Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 5/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653855 | 0.84 | CES2 (0.59) | ESR1ESR2ERN1ALDH1A1HPGD | |
| SCHEMBL9131982 | 0.82 | CA12 (0.56) | ERN1SNCAKDM4EALDH1A1HPGD | |
| SCHEMBL16905393 | 0.81 | HDAC1 (0.58) | ESR1ESR2ERN1LMNAALDH1A1 | |
| SCHEMBL356994 | 0.79 | HDAC1 (0.56) | ESR1ESR2ERN1ALDH1A1HPGD | |
| SCHEMBL16186288 | 0.79 | ERN1 (0.44) | ESR1ESR2ERN1LMNAALDH1A1 | |
| SCHEMBL788674 | 0.79 | ERN1 (0.44) | ESR1ESR2ERN1LMNAALDH1A1 | |
| SCHEMBL850387 | 0.79 | ERN1 (0.44) | ESR1ESR2ERN1ALDH1A1HPGD | |
| SCHEMBL10242017 | 0.78 | ERN1 (0.50) | ESR1ESR2ERN1ALDH1A1HPGD | |
| SCHEMBL12813483 | 0.78 | ERN1 (0.47) | ESR1ESR2ERN1ALDH1A1HPGD | |
| SCHEMBL19454508 | 0.78 | HSP90AA1 (0.44) | ERN1ALDH1A1HPGDSMN1; SMN2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | claimed |
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| EP-2874632-A2 | NOVEL TRIAZINE COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014016849-A9 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014016849-A9 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-03-13 | — | — | WO | disclosed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014016849-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD. (SG) | 2014-01-30 | — | — | WO | disclosed |
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | ESR1 969/4885ESR2 684/4885ACHE 4318/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | ESR1 3611/4885ESR2 3256/4885ACHE 4833/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | ESR1 1757/4885ESR2 582/4885ACHE 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.